SI2010181T1 - Postopki zdravljenja celičnih proliferacijskih motenj z uporabo pirimidindiaminskih spojin - Google Patents
Postopki zdravljenja celičnih proliferacijskih motenj z uporabo pirimidindiaminskih spojinInfo
- Publication number
- SI2010181T1 SI2010181T1 SI200730591T SI200730591T SI2010181T1 SI 2010181 T1 SI2010181 T1 SI 2010181T1 SI 200730591 T SI200730591 T SI 200730591T SI 200730591 T SI200730591 T SI 200730591T SI 2010181 T1 SI2010181 T1 SI 2010181T1
- Authority
- SI
- Slovenia
- Prior art keywords
- cell proliferative
- proliferative disorders
- methods
- pyrimidinediamine compounds
- treating cell
- Prior art date
Links
- 230000002062 proliferating effect Effects 0.000 title abstract 3
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 abstract 1
- 102000000551 Syk Kinase Human genes 0.000 abstract 1
- 108010016672 Syk Kinase Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/407,233 US8227455B2 (en) | 2005-04-18 | 2006-04-18 | Methods of treating cell proliferative disorders |
| PCT/US2007/064511 WO2007124221A1 (en) | 2006-04-18 | 2007-03-21 | Methods of treating cell proliferative disorders by using pyrimidinediamine compounds |
| EP07759007A EP2010181B1 (en) | 2006-04-18 | 2007-03-21 | Methods of treating cell proliferative disorders by using pyrimidinediamine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2010181T1 true SI2010181T1 (sl) | 2011-06-30 |
Family
ID=38477280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200730591T SI2010181T1 (sl) | 2006-04-18 | 2007-03-21 | Postopki zdravljenja celičnih proliferacijskih motenj z uporabo pirimidindiaminskih spojin |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8227455B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2010181B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5204761B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE499102T1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2649549C (cg-RX-API-DMAC7.html) |
| DE (1) | DE602007012677D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2010181T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2364657T3 (cg-RX-API-DMAC7.html) |
| SI (1) | SI2010181T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007124221A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1663242T3 (da) * | 2003-08-07 | 2011-08-01 | Rigel Pharmaceuticals Inc | 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler |
| US8227455B2 (en) * | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| US20090048214A1 (en) * | 2006-11-15 | 2009-02-19 | Rigel Pharmaceuticals, Inc | Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds |
| WO2009003136A1 (en) * | 2007-06-26 | 2008-12-31 | Rigel Pharmaceuticals, Inc. | Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders |
| WO2009029682A1 (en) * | 2007-08-28 | 2009-03-05 | Rigel Pharmaceuticals, Inc. | Combination therapy with syk kinase inhibitor |
| TR201807879T4 (tr) * | 2007-11-07 | 2018-06-21 | Rigel Pharmaceuticals Inc | Bir su ayırma maddesi kullanılarak ıslak granülasyon. |
| AR071891A1 (es) | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| DK2305300T3 (en) | 2008-07-10 | 2016-06-06 | Toray Industries | Pharmaceutical composition for treatment and prevention of cancer |
| JP5603881B2 (ja) * | 2009-01-15 | 2014-10-08 | ライジェル ファーマシューティカルズ， インコーポレイテッド | プロテインキナーゼｃ阻害剤とその使用 |
| US8389515B2 (en) * | 2009-11-20 | 2013-03-05 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and prodrugs and their uses |
| US8618095B2 (en) | 2010-04-13 | 2013-12-31 | Rigel Pharmaceuticals, Inc. | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| MX2012013274A (es) | 2010-05-21 | 2013-05-28 | Chemilia Ab | Novedosos derivados de la pirimidina. |
| JP5744021B2 (ja) | 2010-06-30 | 2015-07-01 | 富士フイルム株式会社 | 新規なニコチンアミド誘導体またはその塩 |
| JP5886411B2 (ja) | 2011-03-24 | 2016-03-16 | ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ | 新規のピリミジン誘導体 |
| WO2012167423A1 (en) | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
| MX339685B (es) | 2011-07-28 | 2016-06-06 | Rigel Pharmaceuticals Inc | Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas. |
| ES2661444T3 (es) | 2011-12-28 | 2018-04-02 | Fujifilm Corporation | Nuevo derivado de nicotinamida o sal del mismo |
| US20130310387A1 (en) | 2012-05-16 | 2013-11-21 | Novartis Ag | Monocyclic Heteroaryl Cycloalkyldiamine Derivatives |
| WO2013189241A1 (zh) * | 2012-06-20 | 2013-12-27 | 上海恒瑞医药有限公司 | 嘧啶二胺类衍生物、其制备方法及其在医药上的应用 |
| CN103804382A (zh) * | 2012-11-05 | 2014-05-21 | 韩文毅 | 一类治疗湿疹的化合物及其用途 |
| CN103102412B (zh) * | 2013-01-29 | 2014-03-26 | 陈仁杰 | 人源抗鼻咽癌LMP2A胞外区抗体Fab及其应用 |
| AU2016209737A1 (en) * | 2015-01-23 | 2017-08-17 | Erasmus University Medical Center Rotterdam | Anti-senescence compounds and uses thereof |
| CN108025013A (zh) * | 2015-08-12 | 2018-05-11 | 博尔托拉制药公司 | 用于治疗骨髓瘤的赛度替尼 |
| IL288519B2 (en) | 2015-11-02 | 2023-09-01 | Blueprint Medicines Corp | inhibitors of ret |
| RU2621187C1 (ru) * | 2016-05-13 | 2017-06-01 | Общество с ограниченной ответственностью "Молекулярные Технологии" | Новая кристаллическая солевая форма 2,2-диметил-6-((4-((3,4,5-триметоксифенил)амино)-1,3,5-триазин-2-ил)амино)-2н-пиридо[3,2-в][1,4]оксазин-3(4н)-она для медицинского применения |
| AU2017325844A1 (en) | 2016-09-14 | 2019-03-07 | Gilead Sciences, Inc. | SYK inhibitors |
| TW201822764A (zh) | 2016-09-14 | 2018-07-01 | 美商基利科學股份有限公司 | Syk抑制劑 |
| WO2018195471A1 (en) | 2017-04-21 | 2018-10-25 | Gilead Sciences, Inc. | Syk inhibitors in combination with hypomethylating agents |
| HRP20240124T1 (hr) | 2018-04-03 | 2024-04-12 | Blueprint Medicines Corporation | Inhibitori za ret za uporabu u liječenju raka koji ima ret alteraciju |
| US12448366B2 (en) | 2020-05-29 | 2025-10-21 | Rigel Pharmaceuticals, Inc. | Solid forms of pralsetinib |
| JPWO2023182460A1 (cg-RX-API-DMAC7.html) * | 2022-03-24 | 2023-09-28 | ||
| WO2024037910A1 (en) * | 2022-08-17 | 2024-02-22 | Institut National de la Santé et de la Recherche Médicale | Syk inhibitors for use in the treatment of cancer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| ATE261730T1 (de) * | 1997-12-31 | 2004-04-15 | Univ Kansas | Wasserlösliche medikamentenvorstufen tertiärer amine enthaltender medikamente und verfahren zu ihrer herstellung |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| CN1307173C (zh) | 2000-12-21 | 2007-03-28 | 葛兰素集团有限公司 | 作为血管生成调节剂的嘧啶胺 |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| WO2003026664A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
| WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
| WO2003055489A1 (en) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| MXPA04008999A (es) * | 2002-03-20 | 2004-12-07 | Squibb Bristol Myers Co | Profarmacos de fosfato de fluorooxindoles. |
| ES2445208T3 (es) | 2002-07-29 | 2014-02-28 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias |
| WO2004014832A2 (en) | 2002-08-02 | 2004-02-19 | Vanetta S.P.A. | Redox process particularly for the production of menadione and use of polyoxometalates |
| WO2004087698A2 (en) | 2003-03-25 | 2004-10-14 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
| PT1656372E (pt) * | 2003-07-30 | 2013-06-27 | Rigel Pharmaceuticals Inc | Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina |
| DK1663242T3 (da) | 2003-08-07 | 2011-08-01 | Rigel Pharmaceuticals Inc | 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler |
| WO2005027848A2 (en) | 2003-09-19 | 2005-03-31 | Barnes-Jewish Hospital | Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators |
| US20050267182A1 (en) * | 2003-11-13 | 2005-12-01 | Ambit Biosciences Corporation | Urea derivatives as FLT-3 modulators |
| JP5095409B2 (ja) | 2004-11-24 | 2012-12-12 | ライジェル ファーマシューティカルズ， インコーポレイテッド | スピロ２，４−ピリミジンジアミン化合物およびその使用 |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| US20090048214A1 (en) | 2006-11-15 | 2009-02-19 | Rigel Pharmaceuticals, Inc | Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds |
-
2006
- 2006-04-18 US US11/407,233 patent/US8227455B2/en active Active
-
2007
- 2007-03-21 CA CA2649549A patent/CA2649549C/en active Active
- 2007-03-21 JP JP2009506662A patent/JP5204761B2/ja active Active
- 2007-03-21 AT AT07759007T patent/ATE499102T1/de not_active IP Right Cessation
- 2007-03-21 EP EP07759007A patent/EP2010181B1/en active Active
- 2007-03-21 WO PCT/US2007/064511 patent/WO2007124221A1/en not_active Ceased
- 2007-03-21 DE DE602007012677T patent/DE602007012677D1/de active Active
- 2007-03-21 SI SI200730591T patent/SI2010181T1/sl unknown
- 2007-03-21 DK DK07759007.3T patent/DK2010181T3/da active
- 2007-03-21 ES ES07759007T patent/ES2364657T3/es active Active
-
2012
- 2012-06-04 US US13/487,979 patent/US8481521B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5204761B2 (ja) | 2013-06-05 |
| CA2649549C (en) | 2011-10-18 |
| JP2009534397A (ja) | 2009-09-24 |
| US8227455B2 (en) | 2012-07-24 |
| EP2010181B1 (en) | 2011-02-23 |
| CA2649549A1 (en) | 2007-11-01 |
| DK2010181T3 (da) | 2011-06-14 |
| US8481521B2 (en) | 2013-07-09 |
| ATE499102T1 (de) | 2011-03-15 |
| ES2364657T3 (es) | 2011-09-08 |
| EP2010181A1 (en) | 2009-01-07 |
| WO2007124221A1 (en) | 2007-11-01 |
| US20120245127A1 (en) | 2012-09-27 |
| DE602007012677D1 (de) | 2011-04-07 |
| US20060276459A1 (en) | 2006-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2010181T1 (sl) | Postopki zdravljenja celičnih proliferacijskih motenj z uporabo pirimidindiaminskih spojin | |
| SG10201811480WA (en) | Therapeutic compounds and compositions | |
| MX342274B (es) | Actividades de la piruvato quinasa m2 (pkm2). | |
| MY163477A (en) | Pyrimidinyl-pyridazinone derivatives | |
| NZ604480A (en) | Morpholino pyrimidines and their use in therapy | |
| WO2010118063A3 (en) | Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use | |
| IL178675A0 (en) | Monocyclic heterocycles as kinase inhibitors | |
| NZ630925A (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| MX2010009268A (es) | Compuestos que son inhibidores de erk. | |
| MX347040B (es) | Inhibidores de tirosina-cinasas. | |
| MY159523A (en) | Triazolopyridazines as tyrosine kinase modulators | |
| IL173722A0 (en) | Proteasome inhibitors and methods of using the same | |
| MY152948A (en) | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors | |
| WO2009011850A3 (en) | Novel therapeutic compounds | |
| EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
| MX336022B (es) | Activadores de pkm2 bicíclicos. | |
| IL184678A0 (en) | Proteasome inhibitors and methods of using the same | |
| MX2011006150A (es) | Compuestos inhibidores de cinasa. | |
| MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
| MX2009008132A (es) | Terapia de combinacion con inhibidores de angiogenesis. | |
| MX2012010212A (es) | Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer. | |
| MX2020003126A (es) | Derivados de iminopirimidina ciclicos como inhibidores de cinasa. | |
| SG10201810575WA (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| MY162518A (en) | Proteasome inhibitors and methods of using the same | |
| NZ596861A (en) | Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer |